Table 1 Clinically Important HPV Genotypes (Adopted from Rerucha et al., 2018)

Genotype		Pathogenesis	Commonly used FDA-approved HPV tests for genotype
			detection and specification
High risk (oncogenic)	Type 16	Causes 50% of all	Pooled detection by Hybrid Capture II HPV DNA test, Cervista
		squamous cell	HPV DNA test, and Aptima HPV mRNA test. Specific detection
		carcinomas of the cervix	by Cobas HPV DNA test
		and 55% to 60% of all	
		cervical cancers	
		worldwide	
	Type 18	Causes 20% of cervical	Pooled detection by Hybrid Capture II HPV DNA test, Cervista
		adenocarcinomas	HPV DNA test, and Aptima HPV mRNA test. Specific detection
			by Cobas HPV DNA test
	Other: types	All types combined cause	Results are not differentiated by type and are reported as
	31, 33, 35, 39,	25% of cervical cancers	positive or negative for these 12 high-risk HPV strains. Pooled
	45, 51, 52, 56,		detection of all types except for type 66 by Hybrid Capture II
	58, 59, (66),		HPV DNA test. Pooled detection of all 14 oncogenic types by
	68		Cervista HPV DNA test, Cobas HPV DNA test, and Aptima
			HPV mRNA test
Low risk	Types 6 and	Cause 90% to 95% of	Testing is not recommended
(wart-causing)	11	anogenital warts	